Yuko Nakamura MD, Presenter: Nothing to Disclose

Wataru Fukumoto, Abstract Co-Author: Nothing to Disclose

Yoko Kaichi, Abstract Co-Author: Nothing to Disclose

Yukiko Honda MD, Abstract Co-Author: Nothing to Disclose

Shuji Date, Abstract Co-Author: Nothing to Disclose

Kazuo Awai MD, Abstract Co-Author: Research Grant, Toshiba Corporation Research Grant, Hitachi Ltd Research Grant, Bayer AG Research Consultant, DAIICHI SANKYO Group Research Grant, Eisai Co, Ltd

a. In patients with liver metastasis from colorectal cancer (LMCRC), surgical resection is the most effective, curative treatment. As both oncologic and functional outcomes are important, current treatment strategies must be understood. b. Gadoxetate disodium (EOB)-enhanced MRI is the preferred modality for detecting LMCRC in untreated patients. PET-CT helps to identify distant metastases and local recurrence. c. The prolonged administration of chemotherapy raises the risk for liver damage such as steatosis, sinusoidal injury, and steatohepatitis. Radiologists must be able to interpret imaging finding after treatments for LMCRC.  

a. Overview of current strategies to treat LMCRC b. Characteristic CT-, MRI-, and PET/CT findings in patients with LMCRC c. Role of these imaging modalities in patients with LMCRC d. Evaluation of imaging findings to determine therapeutic effects: Fundamentals and tips e. Changes in imaging findings due to CRCLM treatments  

http://abstract.rsna.org/uploads/2014/14009656/14009656_qafn.pdf

Nakamura, Y, Fukumoto, W, Kaichi, Y, Honda, Y, Date, S, Awai, K, Liver Metastasis from Colorectal Cancer: What the Radiologists Must Know to Deliver the Best Treatment.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14009656.html